Legal Cannabis and CBD Sales are on the Rise

LAS VEGAS, March 2, 2018 /PRNewswire/ -- Based on data provided by Arcview Market Research, legal cannabis sales in North America totaled $6.7 billion in 2016 and are projected to grow at a compound annual growth rate of 25 percent to an estimated $20.2 billion by 2021. The demand of cannabis from legal markets is expected to increase as more states legalize either recreational or medical use. Consumers in North America spent over $53 billion in the legal and illegal cannabis markets combined in 2016. According to another report from Arcview Market Research, the licensed cannabis stores are as profitable as Starbucks stores and the recreational markets will double the size of the medical market by 2021. Chineseinvestors.com, Inc. (OTC: CIIX), CV Sciences, Inc (OTC: CVSI), Freedom Leaf, Inc. (OTC: FRLF), GB Sciences, Inc. (OTC: GBLX), Isodiol International Inc. (OTC: ISOLF).

A major portion of the legal cannabis industry Cannabidiol products. Cannabidiol, or CBD, is one of at least 113 active cannabinoids identified in cannabis. The CBD market is growing rapidly in recent years due to CBD's medical benefits. Sean Murphy, the Founder and Publisher of Hemp Business Journal, said: "Hemp Business Journal estimates the total retail value of all hemp products sold in the U.S. to be at least $688 million for 2016. We estimate the hemp industry will grow to $1.8 billion in sales by 2020, led by hemp food, body care, and CBD-based products. The data demonstrates the hemp industry is growing quickly at 22% five year CAGR and being led by food and body care products, with Hemp CBD products showing a 53% AGR."

Chineseinvestors.com, Inc. (OTCQB: CIIX) on February 28th announced the details of the stock dividends related to the upcoming spinoff of all hemp-related assets including its China-based wholly owned foreign enterprise, CBD Biotechnology Co. Ltd. ("CBD Biotech") and its wholly owned United States subsidiaries, ChineseHempOil.com, Inc. ("Chinese Hemp Oil") and Hemp Logic, Inc. ("Hemp Logic").

Last month, the Company's subsidiaries achieved combined sales of over $100,000.00 and are well positioned to continue to achieve substantial growth into 2018 and beyond. CIIX plans to spin off all of its hemp related assets including, but not limited to, CBD Biotech, Chinese Hemp Oil and Hemp Logic into a single private company (the "New Company") with the goal being to bring the New Company into the public market in 12 to 18 months that follow. The New Company will issue one share of stock in the New Company for every four shares of CIIX's common stock held by investors as of the date of the spinoff, May 31, 2018.

According to CIIX's CEO, Warren Wang, "We want to provide our shareholders the opportunity to take advantage of this dividend; therefore, we encourage holders of our preferred stock to convert into common prior to May 31, 2018."

CIIX will continue to oversee the progress of the New Company. CIIX's CEO, Mr. Wang, and its CFO, Paul Dickman will serve on the board of directors of the New Company. CIIX is also currently evaluating potential independent board members for the New Company and individuals to join the management team.

CIIX has enjoyed success in helping to support various startup companies through its advertising and public relation related support services. Many of those startup companies have gone on to achieve strong stock prices. We look forward to the Company's spin off continuing this track record of success. Chinese Hemp Oil, Hemp Logic and CBD Biotech represent the Company's only involvement in the hemp industry, with its hemp-based CBD products; therefore, spinning off these entities will completely remove the parent, CIIX, from its involvement in the hemp industry, leaving the New Company to capitalize on the continuously growing hemp industry and other complimentary ventures.

"This is a great time to spin off CIIX's CBD focused assets as we continue to explore new ways to expand its core financial services business, including its recent move into the cryptocurrency and blockchain technology industry," according to ChineseInvestors.com, Inc.'s CFO Paul Dickman.

CV Sciences, Inc (OTCQB: CVSI), located in San Diego, California and Las Vegas, Nevada, focuses on drug development activities on products containing cannabidiol (CBD) as the active pharmaceutical ingredient, and also is engaged in the manufacturing, marketing and sale of end consumer products containing CBD, which is refined into its own PlusCBD Oil(TM) brand. CV Sciences' Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions. CV Sciences' Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Currently distributed nationally in health food stores, health care provider's offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician's recommendations. Recently, the company announced that it will be presenting at 30th Annual ROTH Conference. The Conference is being held on March 11-14, 2018 at The Ritz-Carlton in Dana Point, California.

Freedom Leaf, Inc. (OTCQB: FRLF) is a leading, go-to resource in the cannabis, medical and recreational marijuana, CBD and industrial hemp industries. On January 31, 2018, the company announced a joint venture supply partnership with NutraFuels, Inc. Freedom Leaf CEO Cliff Perry announced, "We have created a strong relationship with NutraFuels as they assisted us in the formulation, blending and private labeling our Ayurvedic Breathable Vapor Oils that are the flagship product in our Hempology (R) line of Full Spectrum Whole-Plant Hemp Extracts."

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. Recently, the company announced a new agreement with the Colorado Hemp Project to develop and cultivate boutique genetics and new strains of hemp which will provide the key ingredient in proprietary CBD formulations. The mission statement of the Colorado Hemp Project is: an organic hemp farm consulting agency that works with local farmers and municipalities across the globe to bring hemp cultivars and resources to the communities that need it the most, with the sole intention of healing the planet by accelerating the establishment of local, sustainable hemp farms and companies everywhere. GB Sciences believes that hemp will provide an important palette upon which important compounds can be created, and believes that, ultimately, hemp will provide a relatively inexpensive source of important and beneficial cannabinoids. GB Sciences will breed CBD into the genetics of the hemp plants and then analyze and optimize results.

Isodiol International Inc. (OTC: ISOLF) is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products. On February 15, 2018, the company announced that it has entered into a Definitive Agreement to acquire 100% of Canadian National Pharma Group Inc., a pharmaceutical manufacturing company. Isodiol previously announced on Dec. 6th, 2017 the agreement to acquire an initial stake representing 25% equity of CN Pharma. The company purchased the remaining 75% equity and is excited to establish CN Pharma as a wholly owned subsidiary. Once approved by Health Canada, CN Pharma will be licensed to process and manufacture controlled substances, handle all cannabis and hemp derivatives, import and export oils and isolates, prepare various formulation and mixtures, participate in research or testing activities, and conduct new product and drug development.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For chineseinvestors.com Inc. financial news dissemination and PR services, FinancialBuzz.com expects to be compensated three thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com Inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

            For further information: 
        info@financialbuzz.com   
        +1-877-601-1879 

 

 

URL: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com


Company Codes: OTC-BB:CIIX, OTC-BB:CVSI, OTC-BB:FRLF, OTC-BB:GBLX, OTC-BB:ISOLF

Back to news